ES2295068T3 - Gamma-hidroxi-2-(fluoroalquilaminocarbonil)-1-piperazinpentanamidas como inhibidores de la proteasa del vih. - Google Patents
Gamma-hidroxi-2-(fluoroalquilaminocarbonil)-1-piperazinpentanamidas como inhibidores de la proteasa del vih. Download PDFInfo
- Publication number
- ES2295068T3 ES2295068T3 ES00980679T ES00980679T ES2295068T3 ES 2295068 T3 ES2295068 T3 ES 2295068T3 ES 00980679 T ES00980679 T ES 00980679T ES 00980679 T ES00980679 T ES 00980679T ES 2295068 T3 ES2295068 T3 ES 2295068T3
- Authority
- ES
- Spain
- Prior art keywords
- hydroxy
- dihydro
- amino
- alkyl
- carbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16747899P | 1999-11-24 | 1999-11-24 | |
| US167478P | 1999-11-24 | ||
| US17705300P | 2000-01-20 | 2000-01-20 | |
| US177053P | 2000-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2295068T3 true ES2295068T3 (es) | 2008-04-16 |
Family
ID=26863215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES00980679T Expired - Lifetime ES2295068T3 (es) | 1999-11-24 | 2000-11-21 | Gamma-hidroxi-2-(fluoroalquilaminocarbonil)-1-piperazinpentanamidas como inhibidores de la proteasa del vih. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6642237B1 (enExample) |
| EP (1) | EP1242426B1 (enExample) |
| JP (1) | JP2003514910A (enExample) |
| AT (1) | ATE377011T1 (enExample) |
| AU (1) | AU777824B2 (enExample) |
| CA (1) | CA2391643C (enExample) |
| CO (1) | CO5261497A1 (enExample) |
| DE (1) | DE60036961T2 (enExample) |
| ES (1) | ES2295068T3 (enExample) |
| PE (1) | PE20011025A1 (enExample) |
| WO (1) | WO2001038332A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9815567D0 (en) * | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
| WO2001055326A2 (en) * | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US7049146B2 (en) | 2000-11-14 | 2006-05-23 | Facet Analytical Services And Technology, Llc | Calibration standards, methods, and kits for water determination |
| US7122376B2 (en) * | 2001-11-01 | 2006-10-17 | Facet Analytical Services And Technology, Llc | Calibration standards, methods, and kits for water determination |
| US6649761B2 (en) | 2001-05-30 | 2003-11-18 | Merck & Co., Inc. | Process for preparing piperazinepentaneamide HIV protease inhibitors |
| WO2002096359A2 (en) * | 2001-05-30 | 2002-12-05 | Merck & Co., Inc. | Piperazine pentanamide hiv protease inhibitors |
| US6835860B2 (en) | 2002-02-01 | 2004-12-28 | Merck & Co., Inc. | Iodohydroxylation of olefins |
| US20040067216A1 (en) * | 2002-02-22 | 2004-04-08 | Karki Shyam B. | Hiv protease inhibitors supported on cation exchange resins for oral administration |
| GB0218876D0 (en) * | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| AU2003270727A1 (en) * | 2002-09-17 | 2004-04-08 | Luna Innovations, Inc. | Remote temperature sensing of small volume and related apparatus thereof |
| US7199240B2 (en) | 2002-12-11 | 2007-04-03 | Merck & Co., Inc. | Reductive alkylation of saturated cyclic amines |
| JP4896518B2 (ja) * | 2002-12-13 | 2012-03-14 | ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド | ニコチンアミド系キナーゼ阻害薬 |
| TW574132B (en) * | 2003-04-14 | 2004-02-01 | Univ Nat Cheng Kung | Integrated microfluidic electro-spray chip system and the analysis method thereof |
| US7161015B1 (en) * | 2005-09-08 | 2007-01-09 | The United States Of America As Represented By The Secretary Of The Navy | Method of making 2-furylalkylketones |
| JP2006316049A (ja) * | 2006-04-11 | 2006-11-24 | Tanabe Seiyaku Co Ltd | ２，２−ジアルコキシエチルアミン化合物およびその製造方法 |
| JP2012528160A (ja) | 2009-05-27 | 2012-11-12 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｈｉｖプロテアーゼ阻害薬 |
| ES2898348T3 (es) | 2009-10-26 | 2022-03-07 | Merck Sharp & Dohme | Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa |
| CA2794952C (en) | 2010-04-01 | 2018-05-15 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
| WO2012052412A1 (de) | 2010-10-22 | 2012-04-26 | Bayer Cropscience Ag | Neue heterocylische verbindungen als schädlingsbekämpfungsmittel |
| WO2012055031A1 (en) | 2010-10-28 | 2012-05-03 | Merck Canada Inc. | Hiv protease inhibitors |
| GB201100181D0 (en) | 2011-01-06 | 2011-02-23 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| GB201101139D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| GB201101140D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| US9226505B2 (en) | 2011-09-23 | 2016-01-05 | Bayer Intellectual Property Gmbh | 4-substituted 1-phenylpyrazole-3-carboxylic acid derivatives as agents against abiotic plant stress |
| EP2771332B1 (en) | 2011-10-26 | 2016-06-29 | Merck Canada Inc. | Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS |
| BR112015005347A2 (pt) | 2012-09-11 | 2017-08-08 | Merck Sharp & Dohme Corp E Merck Canada Inc | composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids |
| WO2015013835A1 (en) | 2013-07-31 | 2015-02-05 | Merck Sharp & Dohme Corp. | Piperazine derivatives as hiv protease inhibitors |
| EP3052132B1 (en) | 2013-09-30 | 2020-07-29 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| WO2015095265A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Hiv protease inhibitors |
| WO2015095276A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Hiv protease inhibitors |
| WO2015134366A1 (en) | 2014-03-06 | 2015-09-11 | Merck Sharp & Dohme Corp. | Hiv protease inhibitors |
| US10138255B2 (en) | 2014-03-10 | 2018-11-27 | Merck Sharp & Dohme Corp. | Piperazine derivatives as HIV protease inhibitors |
| EP2944955A1 (en) * | 2014-05-13 | 2015-11-18 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Benchmark for LC-MS systems |
| MX387903B (es) * | 2014-07-08 | 2025-03-19 | Corteva Agriscience Llc | Proceso para la preparacion de acidos 3-hidroxipicolinicos. |
| CN104311479B (zh) * | 2014-09-15 | 2016-06-15 | 西华大学 | 3,5-二碘-4-羟基吡啶的合成 |
| US9938265B2 (en) * | 2015-11-30 | 2018-04-10 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| WO2019175464A1 (en) | 2018-03-14 | 2019-09-19 | Orion Corporation | Compounds useful as inhibitors of sodium-calcium exchanger (ncx) |
| AR114422A1 (es) | 2018-03-30 | 2020-09-02 | Syngenta Participations Ag | Compuestos herbicidas |
| CN113329629A (zh) | 2018-11-12 | 2021-08-31 | 先正达农作物保护股份公司 | 除草化合物 |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| US12083099B2 (en) | 2020-10-28 | 2024-09-10 | Accencio LLC | Methods of treating symptoms of coronavirus infection with viral protease inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8927913D0 (en) | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| CA2081970C (en) | 1991-11-08 | 1997-07-08 | Joseph P. Vacca | Hiv protease inhibitors useful for the treatment of aids |
| US5484926A (en) | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| IL110255A (en) | 1993-07-16 | 1998-12-06 | Merck & Co Inc | Formation and resolution of 2-tert-butylcarboxamido-piperazine |
| US5455351A (en) * | 1993-12-13 | 1995-10-03 | Abbott Laboratories | Retroviral protease inhibiting piperazine compounds |
| HUT74681A (en) | 1993-12-15 | 1997-01-28 | Merck & Co Inc | N-(2-hydroxy-1-indenyl)-2-phenylmethyl-4-hydroxy-5-(2-carboxamido-piperazinyl)-pentaneamide derivatives of hiv protease inhibitor activity and phrmaceutical compositions contining them |
| IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| TW438799B (en) * | 1997-05-29 | 2001-06-07 | Merck & Co Inc | HIV protease inhibitor |
| WO1999033795A1 (en) * | 1997-12-24 | 1999-07-08 | Vertex Pharmaceuticals Incorporated | Prodrugs of aspartyl protease inhibitors |
-
2000
- 2000-11-21 WO PCT/US2000/032089 patent/WO2001038332A1/en not_active Ceased
- 2000-11-21 JP JP2001540095A patent/JP2003514910A/ja not_active Withdrawn
- 2000-11-21 DE DE60036961T patent/DE60036961T2/de not_active Expired - Lifetime
- 2000-11-21 AU AU17909/01A patent/AU777824B2/en not_active Ceased
- 2000-11-21 CA CA002391643A patent/CA2391643C/en not_active Expired - Fee Related
- 2000-11-21 EP EP00980679A patent/EP1242426B1/en not_active Expired - Lifetime
- 2000-11-21 US US09/718,223 patent/US6642237B1/en not_active Expired - Fee Related
- 2000-11-21 ES ES00980679T patent/ES2295068T3/es not_active Expired - Lifetime
- 2000-11-21 AT AT00980679T patent/ATE377011T1/de not_active IP Right Cessation
- 2000-11-23 CO CO00089726A patent/CO5261497A1/es not_active Application Discontinuation
- 2000-11-24 PE PE2000001259A patent/PE20011025A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE60036961D1 (de) | 2007-12-13 |
| DE60036961T2 (de) | 2008-08-28 |
| CA2391643A1 (en) | 2001-05-31 |
| CA2391643C (en) | 2010-01-12 |
| EP1242426B1 (en) | 2007-10-31 |
| JP2003514910A (ja) | 2003-04-22 |
| ATE377011T1 (de) | 2007-11-15 |
| EP1242426A1 (en) | 2002-09-25 |
| AU1790901A (en) | 2001-06-04 |
| PE20011025A1 (es) | 2001-10-12 |
| CO5261497A1 (es) | 2003-03-31 |
| AU777824B2 (en) | 2004-11-04 |
| US6642237B1 (en) | 2003-11-04 |
| WO2001038332A1 (en) | 2001-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6642237B1 (en) | Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof | |
| CN104892582B (zh) | 作为用于治疗增生性疾病的mek抑制剂的吖丁啶 | |
| JP6349360B2 (ja) | Ｃｂ２アゴニストとして有用なピリジン−２−アミド | |
| KR102616762B1 (ko) | 타겟화된 단백질들의 향상된 분해를 위한 화합물들 및 방법들 | |
| US11807644B2 (en) | Methods and compounds for restoring mutant p53 function | |
| US11098010B2 (en) | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same | |
| KR101877187B1 (ko) | 치환된 다이하이드로이소퀴놀린온 화합물 | |
| CN119019369A (zh) | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 | |
| ES2914677T3 (es) | Compuestos farmacéuticos | |
| CN108137507A (zh) | 基于mdm2的蛋白水解调节剂和相关的使用方法 | |
| TW202204338A (zh) | 半胱胺酸蛋白酶抑制劑及其使用方法 | |
| IL293558A (en) | Functional heterocyclic compounds as modulators of the stimulator of interferon genes (sting) | |
| KR20030019423A (ko) | 프로페논 유도체를 함유하는 의약 조성물 | |
| US10138255B2 (en) | Piperazine derivatives as HIV protease inhibitors | |
| HK1193594B (en) | Pyridin- 2 -amides useful as cb2 agonists | |
| HK1193594A (en) | Pyridin- 2 -amides useful as cb2 agonists |